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ABSTRACT 1 
Polygenic risk scores (PRS) have shown promise in predicting susceptibility to common diseases.1-3  2 
We estimated their added value in clinical risk prediction of five common diseases, using large-3 
scale biobank data (FinnGen; N=135,300), and the FINRISK study with clinical risk factors to test 4 
genome-wide PRSs for coronary heart disease (CHD), type 2 diabetes (T2D), atrial fibrillation 5 
(AF), and breast and prostate cancer. We evaluated the lifetime risk at different PRS levels, and the 6 
impact on disease onset and on prediction together with clinical risk scores. Compared to average 7 
PRS, having a high PRS contributed to 21% to 38% higher lifetime risk, and 4 to 9 years earlier 8 
disease onset. PRS improved model discrimination over age and sex in T2D, AF, breast cancer, and 9 
prostate cancer, and over clinical risk in T2D, breast cancer, and prostate cancer. In all diseases, 10 
PRS improved reclassification over clinical thresholds, with largest net reclassification 11 
improvements for early-onset CHD, AF, and prostate cancer. This study provides evidence for the 12 
additional value of PRS in clinical disease prediction. The practical applications of polygenic risk 13 
information for stratified screening or for guiding lifestyle and medical interventions in the clinical 14 
setting remain to be defined in further studies. 15 
 16 
 17 	  18 
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Common chronic diseases present a huge burden to societies, with an estimated one billion 1 
prevalent cases diagnosed with cardiovascular diseases, diabetes, or neoplasms worldwide.4 2 
Consequently, the development of strategies to prevent these diseases is critically important. To 3 
facilitate prevention, a clear understanding of individual risk is essential to determine whether an 4 
individual warrants an intervention as well as to gauge the impact of different interventions. These 5 
risk models typically incorporate clinical and laboratory-based risk factors, and can identify 6 
individuals at high risk suitable for selective prevention strategies, such as prescribing cholesterol-7 
lowering medications for reducing coronary heart disease (CHD) risk.5 Although clinical risk scores 8 
enable the identification of individuals who may benefit from preventive interventions, they come 9 
with some limitations. For instance, cardiovascular risk calculators fail to identify up to 40% of 10 
persons who develop the diseases, and their utility is limited among young individuals.5,6 For breast 11 
cancer, many reproductive, hormonal, and lifestyle risk factors are common. However, they are 12 
relatively weak predictors, identifying only a small fraction of those at high long-term risk.7 13 
Positive family history is an important risk factor in most cardiometabolic diseases and common 14 
cancers, but its utility is limited by aspects such as the number, age, and type of relatives affected.8 15 
 16 
Large-scale genetic screens comparing disease cases with controls have identified thousands of 17 
genetic loci associated with risk of complex disorders,9 suggesting that genomic information has 18 
become a promising candidate for improving clinical risk assessment.10,11 While, individually, the 19 
associated loci typically modify the disease risks only marginally, for many diseases the cumulative 20 
impact of risk across the genome is considerable.12 Polygenic risk scores (PRS) measuring this 21 
cumulative genetic burden13 have recently been shown to correlate with case status in many 22 
complex diseases including CHD, type 2 diabetes (T2D), and breast cancer.1,2,14 However, limited 23 
information exists regarding both the performance of PRS over the life course in a prospective 24 
setting and their value when integrated with the established clinical risk factors and biomarkers. 25 
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 1 
We set out to test the utility of PRSs derived from large-scale genomic information for predicting 2 
first disease events in five diseases: CHD, T2D, atrial fibrillation or flutter (AF), and breast and 3 
prostate cancer. Specifically, we tested three hypotheses: 1) are the PRS associated with first 4 
disease events over a long follow-up and how much does PRS affect lifetime risk, 2) what is the 5 
impact of PRS on age at disease onset, and 3) what is the impact of PRS on clinical risk prediction? 6 
We tested these hypotheses within the FinnGen study cohort comprising of 135,300 individuals 7 
with genome-wide genotyping and up to 46 years of follow-up. 8 
 9 
We first derived PRSs for the five diseases, CHD, T2D, AF, breast cancer, and prostate cancer by 10 
weighting the individual single nucleotide polymorphisms (SNP) by their effect sizes from 11 
published genome-wide association studies (GWAS) and by accounting for linkage disequilibrium 12 
(LD) between markers. We tested the association between these newly derived PRSs and disease 13 
events within the independent FinnGen study cohort (n = 135,300), which comprised 20,179 14 
individuals with CHD, 17,519 with T2D, 12,809 with AF, 4,960 with breast cancer, and 3,617 with 15 
prostate cancer. FinnGen was comprised of 56.3% women, with mean age 59.2 (standard deviation, 16 
SD 16.6) at the end of follow-up.  17 
 18 
For all five diseases, a higher PRS was strongly associated with a higher incidence rate (Figure 1; 19 
Supplementary Table S1). The hazard ratio (HR) per SD increment was 1.31 for CHD (95% CI 20 
1.29-1.33, p < 1.00x10-300), for T2D 1.74 (1.72-1.77, p < 1.00x10-300), for AF 1.62 (1.59-1.65, p < 21 
1.00x10-300), for breast cancer 1.64 (1.60-1.69, p = 7.40 x10-268), and for prostate cancer 1.83 (1.78-22 
1.90, p = 9.32x10-296). Compared to individuals with average PRS (20-80th percentile of the PRS 23 
distribution), being in the top 2.5% of the distribution translated into HRs ranging from 2.03 in 24 
CHD to 4.07 in prostate cancer (p-values 1.96x10-59 to 1.88x10-317; Supplementary Table S1). 25 
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Similarly, when comparing the average PRS to the lowest 2.5%, the HRs ranged from 0.21 in 1 
prostate cancer to 0.61 in CHD (p-values 5.74 × 10-11 to 7.11x10-64). Investigating goodness-of-fit 2 
indicated that the PRS are well calibrated (Extended Data Fig 1). 3 
 4 
These effect sizes translated to the following increases in lifetime risk: from average PRS (20-80th 5 
percentile) to the top 2.5% of the PRS distribution, the risk increased for CHD from 37.2% (95% CI 6 
36.9-37.5%), to 63.9% (62.3-65.5%) (all categories in Supplementary Table S1). The respective 7 
increases were for T2D from 28.3% (28.0-28.6%) to 66.7% (65.1-68.3%), for AF from 24.4% 8 
(24.1-24.7%) to 61.1% (59.5-62.7%), for breast cancer from 13.3% (13.0-13.6%) to 33.9% (31.8-9 
36.0%), and for prostate cancer from 16.3% (15.9-16.7%) to 50.0% (47.5-52.5%). 10 
 11 
In addition, we built estrogen receptor-negative (ER-negative) and estrogen receptor-positive (ER-12 
positive) breast cancer PRSs (Extended Data Fig. 2). With any breast cancer as the outcome, for 13 
ER-negative PRS the HR for average PRS vs top 2.5% of the PRS distribution was 1.69 (95% CI 14 
1.47-1.95, p = 2.55x10-13) and for ER-positive PRS, 2.72 (95% CI 2.42-3.06, p = 2.52x10-62). 15 
 16 
The higher the PRS, the earlier was the disease onset for all five diseases (Figure 2, Extended Data 17 
Fig. 3, sex-specific results in Extended Data Fig. 4). Compared to individuals with average PRS, 18 
those in the top 2.5% of the distribution had a disease onset 4.35 (CHD), 8.81 (T2D), 6.64 (AF), 19 
4.89 (breast cancer), and 5.53 (prostate cancer) years earlier. The largest difference in age at onset 20 
between the top and bottom 2.5%, 13.4 years, was seen for T2D. For CHD, the differences in age at 21 
disease onset were larger in men than in women (Extended Data Fig. 4).  22 
 23 
In estimating clinical risk, we used the following clinical risk factors: 1) The ASCVD risk 24 
calculator15 used for CHD includes age, sex, total cholesterol (TC), high-density lipoprotein (HDL), 25 
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systolic blood pressure (SBP), blood pressure-lowering medication, diabetes, and smoking status, 2) 1 
T2D analyses include age, sex, body mass index (BMI), history of stroke or CHD, parental history 2 
of any diabetes, SBP, diastolic blood pressure (DBP), HDL, and triglycerides, 3) the CHARGE-AF 3 
calculator16 used for AF includes age, height, weight, SBP, DBP, smoking status, blood pressure-4 
lowering medication, diabetes, heart failure, and history of myocardial infarction, 4) breast cancer 5 
analyses include age, family history of breast cancer, current smoking, BMI, alcohol use disorder, 6 
years of hormone replacement therapy, and having given birth one or more children, and 5) prostate 7 
cancer analyses include age, family history, and history of benign prostate hyperplasia. 8 
 9 
We used only incident cases for comparing PRS to clinical risk calculators (comparison of effect 10 
sizes for PRS in prevalent versus incident cases in Supplementary Table S2). We first assessed the 11 
effect of adding PRS to cardiometabolic clinical risk scores for CHD, T2D, and AF using the 12 
FINRISK study (n = 21,813, mean age at baseline 48.0, 52.7% women) which has major 13 
cardiometabolic risk factors measured (Supplementary Table S3).  For breast and prostate cancers, 14 
the effect of adding PRS to the clinical risk factors was assessed in FinnGen. The number of 15 
incident cases and controls was 1,209 and 18,956 for CHD, 1,346 and 19,684 for T2D, 229 and 16 
10,332 for AF, 742 and 37,099 for breast cancer, and 1,172 and 47,679 controls for prostate cancer. 17 
Overall, the Pearson correlation between polygenic and clinical risk scores was low (r ranging from 18 
-0.01 in AF to 0.11 in T2D), and family history of CHD or T2D had only a minor effect on the 19 
association between polygenic risk and disease (Extended Data Fig. 5; Supplementary Table S4). 20 
 21 
PRS improved model discrimination over age and sex in T2D, AF, breast cancer, and prostate 22 
cancer, and over clinical risk in T2D, breast cancer, and prostate cancer (Table 1). The 23 
improvement in C-index over clinical risk scores ranged from 1.0% in T2D to 3.9% in breast 24 
cancer. We then evaluated the reclassification of individuals across commonly used absolute risk 25 
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thresholds when adding the PRS to the clinical risk scores. These thresholds were 10-year risk 1 
≥7.5% for CHD, 10-year risk ≥33% for T2D, 5-year risk ≥5% for AF, and a 10-year risk ≥5% for 2 
breast and prostate cancer. Adding PRS improved case reclassification with NRI ranging from 4.8% 3 
in T2D (95% CI 3.2-6.3%) to 12.9% in breast cancer (95% CI 9.9-15.9%)(Table 2, Supplementary 4 
Table S5). CHD PRS showed improvement in reclassification in early-onset cases (3.9%, 95% CI 5 
1.6-6.2%) and in late-onset controls (1.5%, 95% CI 0.8-2.3). For T2D and breast cancer, the NRI 6 
was larger for late-onset than for early-onset disease. Lastly, we assessed how often PRS alone is 7 
elevated in early- and late-onset cases (Figure 2). In early-onset cases, this proportion was 12.6% 8 
for CHD, 17.9% for T2D, 27.9% for AF, 10.9% for breast cancer, and 29.9% for prostate cancer.  9 
 10 
The differences in absolute risk across PRS categories in breast and prostate cancer could have an 11 
impact on screening practices. For example, breast cancer screening starts from age 50 in Finland, 12 
when its cumulative incidence reaches 2.0%. To bring the assessment of absolute risk differences 13 
across PRS categories to this screening context, using the FINRISK study we estimated the age 14 
when the cumulative incidence reached 2.0% in the different PRS groups: 44.5 years in PRS 15 
category >97.5%, 45.4 years in 80-97.5%, 50.0 years in 20-80%, and 58.5 years in PRS <20%. 16 
Similarly, a 2% cumulative incidence for prostate cancer in men was reached at age 62. When 17 
estimated across the PRS categories, a 2% cumulative incidence was reached at age 55.6 in PRS 18 
category >97.5%, at 59.4 in 80-97.5%, at 62.4 in 20-80%, and at 69.9 in <20%. 19 
 20 
For the studied diseases, CHD, T2D, AF, breast cancer, and prostate cancer, we show that higher 21 
polygenic risk is associated with higher disease risk. This risk elevation also translated into large 22 
absolute risk differences over the lifespan as well as into large shifts towards earlier disease onset. 23 
We also show that in all five diseases, PRS has additional predictive value in clinical risk 24 
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prediction. Adding PRS to clinical risk prediction improved also reclassification over routinely used 1 
clinical thresholds. 2 
 3 
For many diseases, particularly CHD and breast cancer, previous large studies have demonstrated 4 
strong associations between high polygenic risk and risk of disease.1-3,14,17-19 Many of these studies 5 
have, however, used only tens or hundreds of genetic markers, looked at only prevalent cases in a 6 
cross-sectional setting, or have only a short follow-up. Importantly, a study assessing clinical risk 7 
factors with PRS has not been previously performed at this scale. We modeled the risk conferred by 8 
PRS over the life course, using a dataset with population-level disease prevalence. Moreover, we 9 
predicted new, future disease cases by studying prospectively only incident cases when comparing 10 
the PRS to clinical risk calculators, instead of using prevalent cases, which tend to produce higher 11 
effect sizes and are confounded by secondary prevention such lipid-lowering therapy prescribed in 12 
prevalent CHD. The impact of PRS was similar across all five diseases with respect to identifying 13 
subsets of the population at high risk for disease and at risk for earlier disease onset. The PRS had 14 
similar benefits also in clinical risk prediction, but the implications for clinical decision-making and 15 
the age in which utility was largest, vary between the diseases. 16 
 17 
In CHD, adding PRS to clinical risk prediction showed two patterns with implications for clinical 18 
utility. First, for early-onset CHD, the CHD PRS identified individuals missed by clinical risk 19 
scores, comprising 13% of the early-onset cases. Most cardiovascular risk calculators have been 20 
trained with data on middle-aged individuals, and their ability to identify persons at risk for early-21 
onset CHD is therefore limited.5 Improved identification of these high-risk individuals could allow 22 
for targeted preventive efforts, for instance, targeting cholesterol-lowering treatments or lifestyle 23 
modification may be particularly useful in individuals with a high CHD PRS.20-22 Second, CHD 24 
PRS improved reclassification of older non-case individuals towards lower risk. As age is an 25 
9 
 
 
important risk driver in most cardiovascular risk calculators and can therefore lead to false positives 1 
in older age groups, CHD PRS may potentially reduce overestimation of risk and subsequent 2 
overtreatment. 3 
 4 
Both in early- and late-onset T2D cases, high T2D PRS was the only risk factor in approximately 5 
every sixth individual, but in the reclassification analyses, T2D PRS improved reclassification of 6 
clinical risk prediction only for late-onset disease. T2D PRS may have a role in identifying 7 
individuals for targeted screening, or in personalization of preventative options.23 For AF, the PRS 8 
improved identification of high-risk individuals in both early- and late-onset disease, but also 9 
improved classification of older non-cases towards lower risk. In AF, identification of high-risk 10 
individuals is important for prevention of stroke, a relatively common and potentially severe 11 
consequence of AF. Potential clinical applications for AF PRS include targeted screening for timely 12 
diagnosis, or applying it as a biomarker for risk of stroke.19,24 13 
 14 
For breast and prostate cancer, PRS improved identification of high-risk individuals in both early- 15 
and late-onset disease. In breast cancer, clinical risk prediction improvement was larger for late-16 
onset disease, and in prostate cancer for early-onset disease. For prostate cancer, the older non-cases 17 
were reclassified towards lower risk, which might help prevent overdiagnosis. In many countries 18 
including Finland, breast cancer screening is initiated at age 50, by which approximately 2% of 19 
women have been diagnosed with breast cancer.25,26 In our data, this 2% prevalence was reached at 20 
very different ages in the different PRS categories, with the difference between the tails of the PRS 21 
distribution amounting to 14 years. With similar results for prostate cancer, PRS could bring value 22 
to risk stratification to guide screening recommendations in both cancers, in line with previous 23 
studies, some of which have applied also clinical risk factors.2,3,11,27,28 For breast cancer, the timing 24 
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and frequency of mammography screening could be stratified based on risk, and for prostate cancer, 1 
stratification based on PRS could assist in the decision-making for screening.  2 
 3 
As the data comprised of individuals of European ancestry, PRSs need to be tested also in non-4 
European samples. It is of utmost importance to conduct GWASs in non-Europeans to provide input 5 
for PRS in populations of non-European origin.29 Although our analyses were performed in Finns, 6 
our results are in line with earlier reports from other samples of European origin.1,2,18 A fraction of 7 
individuals in FinnGen were ascertained through hospital biobanks or disease-based cohorts, which 8 
may lead to some overestimation of risks. However, the effects of the PRSs in FinnGen were highly 9 
similar to those in the population-based FINRISK (Supplementary Tables S6-S7, Extended Data 10 
Fig. 6). 11 
 12 
In conclusion, when predicting first disease events, polygenic risk scores identified individuals 13 
missed by established clinical risk prediction models, particularly those at high risk for early-onset 14 
disease. The practical applications of polygenic risk information for stratified screening or for 15 
guiding lifestyle and medical interventions in the clinical setting remain to be defined in further 16 
studies. 17 	  18 
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METHODS 1 
 2 
Individuals 3 
The data comprised of 135,300 Finnish individuals from FinnGen Preparatory Phase Data Freeze 3, 4 
which includes prospective epidemiological and disease-based cohorts, and hospital biobank 5 
samples (Supplementary Table S8). The data, representing roughly 3% of Finnish adult population, 6 
were linked by the unique national personal identification numbers to national hospital discharge 7 
(available from 1968), death (1969-), cancer (1953-), and medication reimbursement (1995-) 8 
registries. 9 
 10 
A subset of FinnGen, the population-based FINRISK study with 21,813 individuals was selected 11 
for analyzing the PRSs together with clinical risk factors. The FINRISK surveys, performed in 12 
1992, 1997, 2002, and 2007 comprised random samples of adults within five geographical areas in 13 
Finland. The baseline data covered self-reported information assessed by questionnaires, 14 
anthropometric measurements, and blood samples. Additional details on the study protocol have 15 
been previously described.30 The Ethics Review Board of the Hospital District of Helsinki and 16 
Uusimaa approved the FinnGen study protocol (HUS/990/2017). The FINRISK analyses were 17 
conducted using the THL biobank permission for project BB2015_55.1. All participants gave 18 
written informed consent. 19 
 20 
Disease endpoints 21 
Using the national registries, we studied the incidence of five diseases: CHD, T2D, AF, breast 22 
cancer, and prostate cancer (diagnoses based on International Classification of Diseases, ICD-8, 23 
ICD-9, and ICD-10 in Supplementary Table S9). Follow-up ended at first-ever diagnosis of the 24 
disease of interest, death, or at the end of follow-up on December 31, 2018, whichever came first. 25 
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 1 
Clinical risk factors  2 
The 10-year risk of hard atherosclerotic cardiovascular disease (ASCVD) was evaluated with the 3 
pooled cohort equations (PCE) according to guidelines,15,31 comprising age, sex, self-reported 4 
ancestry, total cholesterol (TC), high-density lipoprotein (HDL), systolic blood pressure (SBP), 5 
blood pressure-lowering medication, prevalent diabetes, and smoking status. The 10-year risk for 6 
ASCVD was categorized as intermediate to high risk (≥7.5% which often leads to consideration of 7 
preventive medication) or low to borderline risk (<7.5%).31 Analyses on family history for CHD 8 
were based on self-reported parental history of early myocardial infarction (MI). 23 individuals 9 
with missing data for the risk variables were excluded. Participants with prevalent diabetes (n = 10 
671) were excluded from all ASCVD assessments. 11 
 12 
For T2D, we constructed a 10-year risk score that included available risk factors listed in the 13 
American Diabetes Association (ADA) criteria for testing for diabetes or prediabetes in 14 
asymptomatic adults.32 High risk was defined as a 10-year risk exceeding 33%.33 The risk factors 15 
included age, sex, body mass index (BMI, kg/m2), history of stroke or CHD, parental history of any 16 
diabetes, systolic and diastolic blood pressure (SBP, DBP), HDL, and triglycerides. History of 17 
cardiovascular disease was defined as physician-diagnosed CHD or stroke (see Supplementary 18 
Table 2 for definition of coronary heart disease; stroke was any of I61, I63, I64 except I63.6 (ICD-19 
10) or 431, 4330A, 4331A, 4339A, 4340A, 4341A, 4349A, 436 (ICD-9) as the underlying or direct 20 
cause of death, or as the main or side diagnosis at hospital discharge. 82 individuals with missing 21 
data on BMI were excluded from these analyses involving clinical risk assessment of T2D. 22 
 23 
For AF, the clinical score for the 5-year absolute risk for individuals above age 45 was carried out 24 
with the CHARGE-AF score, comprising age, height, weight, SBP, DBP, smoking status, blood 25 
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pressure-lowering treatment, prevalent diabetes, heart failure, and history of MI.16 CHARGE-AF 1 
was revised and the risk was categorized as ≤5% or >5%.16 When taking all calculator components 2 
from the original study, the original CHARGE-AF score showed poor calibration with a mean 5-3 
year risk 0.02% in individuals aged ≥45. To improve calibration, we obtained the mean component 4 
from FINRISK individuals aged 45 to 74, which resulted in a 5-year mean risk of 4.3% (standard 5 
deviation 4.6%). We did not revise the baseline hazard, as the original baseline hazard ≈0.972 was 6 
similar to ours (≈0.977). 85 individuals with missing data for the risk variables were excluded. 7 
 8 
For CHD, T2D, and AF, the clinical risk factors were available in FINRISK. For breast and prostate 9 
cancers, the clinical risk factor comparisons were done in FinnGen. For breast cancer, we modeled 10 
the 10-year risk, with a high-risk definition of ≥5%.34 Due to the lack of absolute risk calculators for 11 
prostate cancer in the general population, we applied these thresholds also for prostate cancer. 12 
 13 
In the cancer analyses, follow-up was restricted to start from Jan 1st, 2000, leading to 742 incident 14 
breast cancer cases with 37,099 controls (mean 10-year risk of 2.0%, SD 2.1%), and 1,172 incident 15 
prostate cancer cases with 47,679 controls (mean 10-year risk 2.6% with SD 4.3%). For breast 16 
cancer, we modeled the 10-year risk using available risk factors: age, family history of breast 17 
cancer, current smoking, BMI, alcohol use disorder, years of hormone replacement therapy 18 
(estrogen-only or estrogen-progestagen preparations), and having given birth to one or more 19 
children. Prostate cancer analyses comprised age, family history, and history of benign prostate 20 
hyperplasia. The detailed definitions are provided next. 21 
 22 
The cancer risk factors were modeled from registry data using available risk factors, limiting 23 
analyses to individuals born before or in 1975. Breast cancer analyses include age (on Jan 1st 2000), 24 
family history of breast cancer (ICD-10 code Z80.3), current smoking, body mass index, years of 25 
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hormone replacement therapy before start of follow-up (individual years with purchases with ATC 1 
codes G03CA, G03FA, G03FB, or G03CA), having given birth one or more children before start of 2 
follow-up (ICD-10 codes O80, O81, O82, O84, O85 and ICD-9 codes 650, 651, 6695, 6696, 6697), 3 
and alcohol use disorder (following diagnoses defined in Kiiskinen et al,35 ICD-10 codes F10, 4 
G31.2, G41.51, G62.1,  I42.6, O35.4, K29.3, K70, K85.2, K86.0, P04.3 X45, Z71.4, E24.4, T51.1-5 
9; ICD-9 codes 291, 303, 305A, 3575A,  4255, 5353A, 5710-3, 5770D-F, 5771C-D, 7607A, 9801-6 
9; ICD-8 codes 291, 303, 5710, 9801-9; medication purchases with ATC codes N07BB01, 7 
N07BB02, N07BB04). Prostate cancer analyses include age (on Jan 1st 2000), family history (Z80), 8 
and history of benign prostate hyperplasia before start of follow-up. 9 
 10 
For comparing early- and late-onset cases, the definition for early-onset cases was age below 55 for 11 
CHD, 45 for T2D, 60 for AF, 45 for breast cancer, and 55 for prostate cancer.  12 
 13 
Genotyping and imputation in FinnGen 14 
FinnGen samples were genotyped with Illumina and Affymetrix arrays (Illumina Inc., San Diego, 15 
and Thermo Fisher Scientific, Santa Clara, CA, USA) and put through the same rigorous QC steps 16 
as described below. Genotype imputation was carried out by using the population-specific SISu v3 17 
imputation reference panel with Beagle 4.1 (version 08Jun17.d8b, 18 
https://faculty.washington.edu/browning/beagle/b4_1.html) as described in the following protocol: 19 
dx.doi.org/10.17504/protocols.io.nmndc5e. Post-imputation QC involved excluding variants with 20 
imputation INFO <0.7.  21 
 22 
Genotyping and imputation in FINRISK 23 
26,404 FINRISK samples were genotyped using several arrays: the HumanCoreExome BeadChip, 24 
the Human610-Quad BeadChip, the Affymetrix6.0, and the Infinium HumanOmniExpress 25 
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(Illumina Inc., San Diego and Affymetrix, Inc., Santa Clara, CA, USA). Genotype calls were 1 
generated together with other available data sets using zCall at the Institute for Molecular Medicine 2 
Finland (FIMM). After sample-wise quality control (exclude samples with ambiguous gender, 3 
missingness (>5%), excess heterozygosity (+-4SD), non-European ancestry) and variant-wise 4 
quality control (exclude SNPs with high missingness (>2%), low HWE P-value (<1e-6), minor 5 
allele count (MAC) <3 (in case Zcall'ed chip data) or  MAC <10 (chip data called using Illumina 6 
GenCall) steps, the samples were pre-phased using Eagle2 (version 2.3). Genotype imputation was 7 
carried out by using a Finnish population-specific reference panel consisting of 2,690 high-coverage 8 
WGS and 5,092 WES samples with IMPUTE2 (version 2.3.2) that allows the usage of two panels at 9 
the same time (the ‘merge_ref_panels’ option). Post-imputation quality control involved excluding 10 
variants imputed with imputation INFO < 0.7. Chromosome X variants were also excluded from the 11 
downstream analyses. We excluded one individual of each sample-pair with kinship >0.125, and 12 
calculated principal components for the unrelated individuals. The 26,404 samples contained the 13 
2012 FINRISK cohort; this study used only FINRISK cohorts from 1992, 1997, 2002, and 2007, 14 
comprising 21,813 individuals. 15 
 16 
Polygenic risk scores 17 
In all five diseases, we used external GWAS for building the PRS. The summary association 18 
statistics came from recent GWAS (Supplementary Table S10, Extended Data Fig. 7).17,36-39 LDpred 19 
was used to account for linkage disequilibrium among loci,40 with whole-genome sequencing data 20 
on 2,690 Finns serving as the LD reference panel (using only autosomes). After performing quality 21 
control, the final scores were generated with PLINK224 by calculating the weighted sum of risk 22 
allele dosages for each SNP. The final PRSs comprised 6,412,950 variants for CHD PRS, 6,437,380 23 
for T2D PRS, 6,171,733 for AF PRS, 6,390,808 for breast cancer PRS, and 6,606,785 for prostate 24 
16 
 
 
cancer PRS (candidate LDpred scores concerning the tuning parameter in Supplementary Table 1 
S11). 2 
 3 
Due to the high LD in the isolated Finnish population, we selected an LD-radius approximately 4 
twice the radius recommended, which is M/3,000, where M is the total number of single nucleotide 5 
polymorphisms used in the analysis. Variants with minor allele frequency less than 1% are excluded 6 
by the software. 7 
 8 
We calculated the polygenic risk scores by summing the dosage of each risk allele carried by an 9 
individual (ranging from 0 to 2 for each variant, dosage used for incorporating imputation 10 
uncertainty), weighting each variant by its natural logarithm of the relative risk extracted from the 11 
genome-wide association study.  For each individual i, this results in a single value on a continuous 12 
scale: 13 
PRS푖 = ∑ b̂j ×  푑표푠푎푔푒푖푗푀푗=1   14 
 15 
where b̂j is the weight for variant j obtained from GWAS summary statistics.  16 
 17 
Statistical analysis 18 
Cox proportional hazards model was used to estimate survival curves and hazard ratios (HRs) and 19 
95% confidence intervals (CI). Schoenfeld residuals and log-log inspection showed that 20 
proportional assumption criteria applied in our models. Unless otherwise stated, we adjusted for 21 
FINRISK survey collection year (in FINRISK), genotyping array/batch, the first ten principal 22 
components of ancestry, and stratified the models by sex. Breast cancer was studied only in women 23 
and prostate cancer only in men. Lifetime risk by age 80 was estimated from the adjusted survival 24 
curves with confidence intervals for lifetime risks obtained by normal approximation. Performance 25 
17 
 
 
metrics were calculated with risk measures and PRS on the continuous scale. Model discrimination 1 
was assessed with the concordance index (C-index; confidence intervals obtained by normal 2 
approximation), which is an extension of the area under the receiver operating characteristic curve 3 
to survival analysis. Goodness-of-fit for the Cox proportional hazards model was assessed with R 4 
package survMisc, following methodology proposed by May & Hosmer.41 5 
 6 
We then evaluated improvements in clinical risk stratification when adding PRS to the clinical risk 7 
score. We report the number of individuals reclassified across following clinical thresholds: 10-year 8 
risk ≥7.5% for CHD, 10-year risk ≥33% for T2D, 5-year risk ≥5% for AF, and a 10-year risk ≥5% 9 
for breast and prostate cancer. Reclassification was also assessed with net reclassification 10 
improvement (NRI). In C-index and NRI comparisons, the PRS was added to the linear predictor 11 
alongside the original regression coefficients for the risk factors in the clinical risk scores (ASCVD 12 
for CHD and CHARGE-AF for AF), or as an independent risk factor in the regression model (breast 13 
and prostate cancer; T2D using the ADA high-risk definition variables on their original scale). For 14 
the linear predictor, the effect sizes for CHD PRS (β = 0.222 in women and β = 0.271 in men, per 15 
SD increase) and AF PRS (β = 0.539 per SD increase) were obtained from models fitted in 16 
FINRISK when adjusting for the risk factors included the original risk calculators.  Reclassification 17 
was assessed also separately for early- and late-onset disease by dividing individuals into groups 18 
according to age at baseline (55 for CHD, 45 for T2D, 60 for AF, 45 for breast cancer, and 55 for 19 
prostate cancer). 20 
 21 
We chose 2.5% as our top tail and divided the PRS into bins of <2.5%, 2.5-20%, 20-80%, 80-22 
97.5%, and >97.5%. The 20-80% bin was used as the reference, to display the results with respect 23 
to a large group of individuals with average risk. The definition of the top and bottom 2.5% also 24 
18 
 
 
follows the principle, where a reference range of a laboratory test is often defined by selecting 1 
values within which 95 percent of the population fall. 2 
 3 
Comparing high clinical and high polygenic risk separately for early and late-onset cases, we 4 
calculated the proportion of individuals exceeding the absolute risk thresholds applied in the clinical 5 
risk calculators, which was 10.4% (CHD, with 10-year risk ≥7.5%), 38.4% (T2D, with 10-year risk 6 
≥33%), 10.7% (AF, with 5-year risk ≥5%), 4.8% (breast cancer with 10-year risk ≥5%), and 13.9% 7 
(prostate cancer with 10-year risk ≥5%). Based on these, we defined elevated PRS as a polygenic 8 
risk score above the 90th percentile.  9 
 10 
In FINRISK analyses, the association between PRS and the disease was tested for incident cases 11 
only. The number of prevalent cases excluded in FINRISK was 954 for coronary heart disease, 671 12 
for T2D, 351 for atrial fibrillation (AF), 164 for breast cancer, and 59 for prostate cancer. The 13 
FINRISK had 1,805 individuals overlapping with the AF GWAS, and we excluded these 14 
individuals from the AF analyses. Age at disease onset and the differences between PRS categories 15 
were estimated with restricted mean survival time (RMST).42 RMST (age 85 as the upper limit) 16 
were estimated by fitting flexible parametric survival models, which generated very similar effect 17 
sizes as the Cox proportional hazards models. Adjusted survival curves were plotted with the R 18 
package survminer, using the calculation parameter “conditional”, which after rebalancing averages 19 
for the polygenic risk score categories. For statistical analyses, we used R 3.5.2, and Stata 14.2 20 
(College Station, TX, USA).  21 
 22 	  23 
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Reporting summary 1 
Further information on research design is available in the Nature Research Reporting Summary 2 
linked to this article.	  3 
20 
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Figure 1. Adjusted survival curves from Cox proportional hazards models, showing the cumulative risk of disease by polygenic risk score (PRS) categories in 
FinnGen (n = 135,300 individuals).  
 
 
 
 
CHD = coronary heart disease, AF = atrial fibrillation or flutter, T2D = type 2 diabetes. P-values for trend: CHD p = 2.80 × 10-256; T2D p <1.00 × 10-300; AF p <1.00 × 10-300; breast cancer p = 
3.07 × 10-183; prostate cancer p = 2.41 × 10-243. Incident and prevalent cases included. All tests were two-tailed.
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Table 1. C-index for model discrimination assessed for combinations of age, sex, disease-specific polygenic risk score (PRS) and clinical risk scores.  
 
 N total N cases Age + sex* Age + sex* + PRS Clinical Clinical + PRS 
CHD 20,165 1,209 0.830 (0.825-0.834) 0.832 (0.828-0.836) 0.823 (0.819-0.827) 0.820 (0.816-0.824) 
T2D 21,030 1,346 0.728 (0.723-0.733) 0.763 (0.758-0.767) 0.835 (0.831-0.839) 0.845 (0.841-0.849) 
AF 10,561 229 0.709 (0.702-0.716) 0.751 (0.744-0.757) 0.725 (0.719-0.732) 0.734 (0.728-0.741) 
Breast cancer 37,841 742 0.693 (0.689-0.696) 0.737 (0.733-0.741) 0.711 (0.707-0.714) 0.750 (0.746-0.753) 
Prostate cancer 48,851 1,172 0.827 (0.824-0.829) 0.857 (0.855-0.859) 0.840 (0.837-0.842) 0.866 (0.863-0.868) 
 
 
 
*Sex not included for breast and prostate cancer. CHD = coronary heart disease, AF = atrial fibrillation or flutter, T2D = type 2 diabetes. Only incident cases included. Time 
horizons: 10-year risk for CHD, T2D, breast and prostate cancer; 5-year risk for AF. Clinical risk factors: The ASCVD risk calculator used for CHD includes age, sex, total 
cholesterol, high-density lipoprotein, systolic blood pressure, blood pressure-lowering medication, diabetes, and smoking status; T2D analyses include age, sex, body mass 
index, history of stroke or CHD, parental history of diabetes, systolic and diastolic blood pressure, high-density lipoprotein, and triglycerides; the CHARGE-AF calculator 
used for AF includes age, height, weight, systolic and diastolic blood pressure, smoking status, blood pressure-lowering medication, diabetes, heart failure, and history of 
myocardial infarction; breast cancer analyses include age, family history of breast cancer, current smoking, body mass index, alcohol use disorder, years of hormone 
replacement therapy, and having given birth one or more children; prostate cancer analyses include age, family history, and history of benign prostate hyperplasia. PRS was 
added to the linear predictor of existing continuous calculators (ASCVD15 for CHD, CHARGE-AF16 for AF), or in the case of individual risk factors as an independent 
covariate in the regression model (T2D, breast cancer, prostate cancer). 	  
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Table 2. Net reclassification improvement (NRI) with addition of polygenic risk score (PRS) to clinical risk scores.  
 
     All individuals     Early-onset       Late-onset      
     Individuals reclassified NRI Individuals reclassified NRI Individuals reclassified NRI  
     Up (%) Down (%) Value (%) 95% CI  Up (%) Down (%) Value (%) 95% CI  Up (%) Down (%) Value 95% CI   
CH
D 
N 
= 2
0,1
65
 Cases 2.5 1.6 0.9 -0.2, 2.0  4.4 0.6 3.9 1.6, 6.2  1.7 2.0 -0.4 -1.6, 0.9   
Non-cases 2.1 2.3 0.2 -0.1, 0.5  1.7 1.3 -0.4 -0.7, -0.1  3.1 4.6 1.5 0.8, 2.3   
All - - 1.1 -0.1, 2.2  - - 3.5 1.2, 5.8  - - 1.2 -0.3, 2.7   
T2
D 
N 
= 2
1,0
30
 Cases 6.6 1.9 4.8 3.2, 6.3  1.4 1.0 0.5 -1.6, 2.6  7.6 2.0 5.5 3.7, 7.3   
Non-cases 0.8 0.5 -0.1 -0.2, -0.1  0.1 <0.1 -0.3 -0.2, 0.0  1.3 1.0 -0.3 -0.6, -0.1   
All - - 4.5 3.0, 6.1  - - 0.4 -1.7, 2.5  - - 5.2 3.4, 7.0   
AF
 
N 
= 1
0,5
61
 Cases 16.2 3.5 12.7 6.9, 18.4  24.7 4.3 20.4 9.5, 31.4  10.3 2.9 7.4 1.2, 13.5   
Non-cases 7.7 5.0 -2.7 -3.4, -2.0  7.3 1.6 -5.7 -6.4, -5.0  8.5 11.5 3.0 1.6, 4.5   
All - - 10.0 4.2, 15.7  - - 14.8 3.8, 25.7  - - 10.4 4.1, 16.7   
Br
ea
st 
ca
nc
er
 
N 
= 3
7,8
41
 Cases 15.2 2.3 12.9 9.9, 15.9  3.2 0.6 2.6 -0.5, 5.6  18.4 2.7 15.7 12.0, 19.4   
Non-cases 4.2 2.0 -2.2 -2.5, -2.0  0.4 <0.1 -0.3 -0.4, -0.3  7.8 3.9 -3.9 -4.4, -3.4   
All - - 10.7 7.7, 13.7  - - 2.2 -0.8, 5.3  - - 11.8 8.0, 15.5   
Pr
os
tat
e c
an
ce
r  
N 
= 4
8,8
51
 Cases 14.3 6.4 7.9 5.3, 10.5  18.3 2.7 15.6 10.8, 20.5  12.7 7.9 4.8 1.7, 7.9   
Non-cases 3.3 4.2 0.8 0.6, 1.1  1.8 0.8 -0.9 -1.1, -0.8  8.1 14.1 6.0 5.2, 6.9   
All - - 8.8 6.1, 11.4  - - 14.7 9.8, 19.6  - - 10.8 7.6, 14.0   
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CHD = coronary heart disease, AF = atrial fibrillation or flutter, T2D = type 2 diabetes. Only incident cases included. Reclassification proportion of cases calculated with all 
cases in the denominator, with a similar approach for controls. Reclassification thresholds: 10-year risk ≥7.5% for CHD, 10-year risk ≥33% for T2D, 5-year risk ≥5% for AF, 
and a 10-year risk ≥5% for breast and prostate cancer. Clinical risk scores based on following risk factors: The ASCVD risk calculator used for CHD includes age, sex, total 
cholesterol, high-density lipoprotein, systolic blood pressure, blood pressure-lowering medication, diabetes, and smoking status; T2D analyses include age, sex, body mass 
index, history of stroke or CHD, parental history of diabetes, systolic and diastolic blood pressure, high-density lipoprotein, and triglycerides; the CHARGE-AF calculator 
used for AF includes age, height, weight, systolic and diastolic blood pressure, smoking status, blood pressure-lowering medication, diabetes, heart failure, and history of 
myocardial infarction; breast cancer analyses include age, family history of breast cancer, current smoking, body mass index, alcohol use disorder, years of hormone 
replacement therapy, and having given birth one or more children; prostate cancer analyses include age, family history, and history of benign prostate hyperplasia. Early- and 
late-onset assessment performed by dividing individuals into groups according to age at baseline (55 for CHD, 45 for T2D, 60 for AF, 45 for breast cancer, and 55 for prostate 
cancer).
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Figure 2.  The proportion early- and late-onset cases with high clinical risk, high polygenic risk, or neither.  
 
 
 
CHD = coronary heart disease, AF = atrial fibrillation or flutter, T2D = type 2 diabetes. High PRS = in top decile of the distribution. 
The number of early- and late-onset cases for CHD was 190 and 1,019, for T2D 117 and 1,229, for AF 61 and 168, for breast cancer 
46 and 696, and for prostate cancer 77 and 1,095. CHD, T2D, and AF cases from FINRISK and breast and prostate cancer from 
FinnGen, all incident cases. Clinical high risk definitions were following: For CHD, the 10-year risk calculator for hard 
atherosclerotic cardiovascular disease (ASCVD) ≥7.5%, according to the Pooled Cohort Equations by ACC/AHA (2013); for T2D, a 
10-year risk ≥33% when constructing a calculator with risk factors listed in the American Diabetes Association (ADA) criteria for 
testing for diabetes or prediabetes in asymptomatic adults; for AF, the 5-year risk of AF >5%, by a revised version of the CHARGE-
AF; for breast and prostate cancer a 10-year risk ≥5% with clinical risk factors. 
 
 1 
Table S1. Hazard ratios (HR) and 95% confidence intervals (CI) for polygenic risk score (PRS) bins in FinnGen. 
 
 
  HR (95% CI) Lifetime risk, % (95% CI) p Cases / Controls 
CHD PRS     
<2.5 0.61 (0.55-0.69) 23.2 (21.8-24.6) 3.04 × 10-18 329 / 3,054 
2.5-20 0.72 (0.69-0.75) 27.2 (26.6-27.8) 2.41 × 10-53 2,580 / 21,097 
20-80 1 (reference) 37.2 (36.9-37.5) - 11,832 / 69,348 
80-97.5 1.38 (1.34-1.43) 49.1 (48.5-49.7) 1.30 × 10-76 4,532 / 19,145 
>97.5 2.03 (1.90-2.18) 63.9 (62.3-65.5) 2.87 × 10-93 906 / 2,477 
T2D PRS     
<2.5 0.22 (0.19-0.27) 8.3 (7.4-9.3) 7.11 × 10-64 131 / 3,195 
2.5-20 0.48 (0.46-0.51) 15.9 (15.4-16.4) 1.90 × 10-157 1,653 / 21,548 
20-80 1 (reference) 28.3 (28.0-28.6) - 9,869 / 68,998 
80-97.5 1.92 (1.85-1.99) 46.2 (45.6-46.8) 7.04 × 10-287 4,776 / 17,970 
>97.5 3.45 (3.24-3.67) 66.7 (65.1-68.3) 1.88 × 10-317 1,090 / 2,072 
AF PRS     
<2.5 0.39 (0.33-0.46) 10.3 (9.3-11.3) 1.34 × 10-27 136 / 3,247 
2.5-20 0.56 (0.53-0.59) 15.9 (15.4-16.4) 3.92 × 10-81 1,281 / 22,396 
20-80 1 (reference) 24.4 (24.1-24.7) - 7,159 / 74,021 
80-97.5 1.81 (1.73-1.88) 39.5 (38.9-40.1) 3.57 × 10-177 3,417 / 20,260 
>97.5 3.50 (3.26-3.77) 61.1 (59.5-62.7) 2.11 × 10-250 816 / 2,567 
Breast cancer PRS     
<2.5 0.28 (0.20-0.40) 3.6 (2.8-4.4) 5.24 × 10-13 33 / 1,873 
2.5-20 0.54 (0.49-0.60) 7.5 (7.1-7.9) 4.61 × 10-32 421 / 12,918 
20-80 1 (reference) 13.3 (13.0-13.6) - 2,703 / 43,030 
80-97.5 1.88 (1.77-2.01) 23.8 (23.1-24.5) 5.32 × 10-85 1,483 / 11,856 
>97.5 2.87 (2.56-3.23) 33.9 (31.8-36.0) 1.10 × 10-70 320 / 1,586 
Prostate cancer PRS     
<2.5 0.21 (0.13-0.34) 3.5 (2.6-4.4) 5.74 × 10-11 18 / 1,459 
2.5-20 0.43 (0.37-0.49) 7.4 (6.9-7.9) 7.47 × 10-36 242 / 10,095 
20-80 1 (reference) 16.3 (15.9-16.7) - 1,934 / 33,507 
80-97.5 2.08 (1.93-2.24) 30.7 (29.8-31.6) 4.86 × 10-84 1,118 / 9,219 
>97.5 4.07 (3.61-4.60) 50.0 (47.5-52.5) 8.09 × 10-114 305 / 1,172 
 
 
CHD = coronary heart disease, AF = atrial fibrillation or flutter, T2D = type 2 diabetes. Incident and prevalent cases included. The 
estimates were obtained from Cox proportional hazards models described in detail in the Methods. All tests were two-tailed. 	  
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Table S2. Odds ratios and 95% confidence intervals per standard deviation increase in the polygenic risk scores (PRS) 
in FINRISK (n = 21,813 with detailed information in Supplementary Table S3), demonstrating how in most diseases 
using prevalent cases yields higher effect sizes compared to analyses with only incident cases. We therefore used only 
incident cases for analyses comparing PRS to clinical risk assessment. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHD = coronary heart disease, AF = atrial fibrillation or flutter, T2D = type 2 diabetes. All tests were two-tailed. 	  
  Prevalent only Incident only Incident and prevalent 
CHD 1.58 (1.46-1.70) 1.31 (1.25-1.38) 1.38 (1.32-1.44) 
T2D 2.04 (1.85-2.25) 1.80 (1.71-1.89) 1.83 (1.75-1.92) 
AF 1.88 (1.68-2.10) 1.71 (1.61-1.81) 1.73 (1.64-1.82) 
Breast cancer 1.73 (1.48-2.03) 1.77 (1.60-1.96) 1.77 (1.62-1.93) 
Prostate cancer 2.29 (1.75-3.00) 2.00 (1.81-2.22) 2.04 (1.85-2.25) 
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Table S3. Baseline characteristics for FINRISK. 
 
 FINRISK 1992 FINRISK 1997 FINRISK 2002 FINRISK 2007 
  N = 4,745 N = 6,733 N = 5,427 N = 4,908 
Follow-up in years, mean (SD) 22.3 (4.3) 17.5 (3.7) 13.3 (2.0) 8.7 (1.0) 
Age, mean (SD) 44.3 (11.4) 48.2 (13.4) 48.3 (13.1) 51.1 (13.9) 
Age ≤50, % 65.9 54.9 52.4 45.2 
Women, % 53.8 51.0 53.4 53.3 
     
Current smokers, % 28.0 23.6 26.3 19.9 
TC, mean (SD) 5.6 (1.1) 5.5 (1.1) 5.6 (1.1) 5.3 (1.0) 
LDL, mean (SD) 3.5 (1.0) 3.5 (0.9) 3.4 (1.0) 3.2 (0.9) 
HDL, mean (SD) 1.4 (0.3) 1.4 (0.4) 1.5 (0.4) 1.4 (0.4) 
TG, mean (SD) 1.5 (1.1) 1.5 (1.0) 1.4 (1.0) 1.4 (0.9) 
SBP, mean (SD) 135.3 (19.3) 136.0 (19.9) 135.2 (20.0) 136.2 (20.3) 
BMI, mean (SD) 26.1(4.4) 26.6 (4.5) 26.9 (4.7) 27.2 (4.9) 
WHR, mean (SD) 0.8 (0.1) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 
Blood pressure-lowering treatment, % 9.0 13.0 14.3 21.3 
Lipid-lowering treatment, % 1.5 3.2 7.1 14.6 
Positive family history for any diabetes, % N/A 25.8 26.4 28.7 
Positive family history for early MI, % 23.6 25.5 25.6 15.5 
     
ASCVD risk, mean (SD) 4.4 (5.5) 6.0 (7.9) 5.7 (7.3) 6.6 (7.9) 
CHARGE-AF, mean (SD) 2.7 (2.3) 4.4 (4.8) 4.3 (4.4) 5.7 (5.6) 
T2D risk, mean (SD) 4.6 (7.3) 6.3 (9.5) 8.0 (11.2) 8.9 (11.3) 
     
Prevalent CHD, % 3.3 5.3 5.0 6.4 
Prevalent MI, % 0.8 1.3 1.0 1.7 
Prevalent AF, % 0.9 1.8 1.7 2.9 
Prevalent T2D, % 0.4 2.8 3.8 4.5 
Prevalent breast cancer in women, % 1.0 1.2 1.3 2.3 
Prevalent prostate cancer in men, % 0.0 0.6 0.5 1.2 
Incident CHD, % 14.2 13.8 8.8 5.3 
Incident MI, % 5.6 5.7 3.7 2.0 
Incident AF, % 9.5 9.1 6.0 4.0 
Incident T2D, % 15.7 13.2 10.1 7.2 
Incident breast cancer in women, % 5.3 4.1 3.0 1.5 
Incident prostate cancer in men, % 5.5 5.6 3.6 2.0 
     
TC = total cholesterol, LDL = low-density lipoprotein (using the Friedewald equation), HDL = high-density lipoprotein, TG = 
triglycerides, SBP = systolic blood pressure, BMI = body mass index, WHR = waist-hip ratio, CHD = coronary heart disease, MI 
= myocardial infarction. T2D = type 2 diabetes, AF = atrial fibrillation or flutter. Units: lipid measurements mmol/l, SBP mmHg, 
BMI kg/m2. ASCVD = the 10-year risk calculator for hard atherosclerotic cardiovascular disease according to the Pooled Cohort 
Equations by ACC/AHA (2013). CHARGE AF = AF risk calculator. ASCVD, CHARGE-AF and T2D risk contains only incident 
cases and controls. 
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Table S4. Impact of family history on polygenic risk score (PRS) effect size estimates (per standard deviation increment) 
in FINRISK (total n = 21,813; detailed information in Supplementary Table S3), obtained from Cox proportional hazards 
models. 
 
  HR (95% CI) p 
CHD PRS 1.27 (1.22-1.32) 4.77x10-28 
Family history of early MI 1.49 (1.36-1.63) 7.57x10-18 
CHD PRS + family history of early MI   
CHD PRS 1.26 (1.21-1.31) 5.24x10-26 
Family history of early MI 1.45 (1.32-1.59) 1.21x10-15 
   
T2D PRS 1.57 (1.50-1.66) 1.24x10-68 
Family history of any diabetes 1.62 (1.47-1.78) 1.67x10-22 
T2D PRS + family history of any diabetes   
T2D PRS 1.54 (1.46-1.62) 2.24x10-62 
Family history of any diabetes 1.49 (1.35-1.64) 8.27x10-16 
   
 
CHD = coronary heart disease, T2D = type 2 diabetes. T2D models adjusted for BMI. Only incident cases included. All tests were two-tailed. 
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Table S5. Number and proportion of individuals reclassified with addition of polygenic risk score (PRS) to clinical risk assessment. 
 
    All Early-onset Late-onset 
    Individuals reclassified Individuals reclassified Individuals reclassified 
    Up (%) Down (%) Up (%) Down (%) Up (%) Down (%) 
CH
D Cases 30 (2.5) 19 (1.6) 16 (4.4) 2 (0.6) 14 (1.7) 17 (2.0) 
Non-cases 397 (2.1) 428 (2.3) 234 (1.7) 183 (1.3) 163 (3.1) 245 (4.6) 
T2
D Cases 89 (6.6) 25 (1.9) 3 (1.4) 2 (1.0) 86 (7.6) 23 (2.0) 
Non-cases 152 (0.8) 107 (0.5) 12 (0.1) 3 (<0.1) 140 (1.3) 104 (1.0) 
AF
 Cases 37 (16.2) 8 (3.5) 23 (24.7) 4 (4.3) 14 (10.3) 4 (2.9) 
Non-cases 796 (7.7) 517 (5.0) 496 (7.3) 110 (1.6) 300 (8.5) 407 (11.5) 
Br
ea
st 
ca
nc
er Cases 113 (15.2) 17 (2.3) 5 (3.2) 1 (0.6) 108 (18.4) 16 (2.7) 
Non-cases 1,576 (4.2) 755 (2.0) 68 (0.4) 6 (<0.1) 1,508 (7.8) 749 (3.9) 
Pr
os
tat
e 
ca
nc
er  Cases 168 (14.3) 75 (6.4) 62 (18.3) 9 (2.7) 106 (12.7) 66 (7.9) 
Non-cases 1,593 (3.3) 1,986 (4.2) 625 (1.8) 294 (0.8) 968 (8.1) 1,692 (14.1) 
 
 
CHD = coronary heart disease, AF = atrial fibrillation or flutter, T2D = type 2 diabetes. Reclassification proportion in cases calculated with all cases in the denominator, with a similar approach 
for controls. Reclassification thresholds: 10-year risk ≥7.5% for CHD, 10-year risk ≥33% for T2D, 5-year risk ≥5% for AF, and a 10-year risk ≥5% for breast and prostate cancer. Clinical risk 
assessment based on following risk factors: The ASCVD risk calculator used for CHD includes age, sex, total cholesterol, high-density lipoprotein, systolic blood pressure, blood pressure-lowering 
medication, diabetes, and smoking status; T2D analyses include age, sex, body mass index, history of stroke or CHD, parental history of diabetes, systolic and diastolic blood pressure, high-density 
lipoprotein, and triglycerides; the CHARGE-AF calculator used for AF includes age, height, weight, systolic and diastolic blood pressure, smoking status, blood pressure-lowering medication, 
diabetes, heart failure, and history of myocardial infarction; breast cancer analyses include age, family history of breast cancer, current smoking, body mass index, alcohol use disorder, years of 
hormone replacement therapy, and having conceived one or more children; prostate cancer analyses include age, family history, and history of benign prostate hyperplasia. Early- and late-onset 
assessment performed by dividing individuals into groups according to age at baseline (55 for CHD, 45 for T2D, 60 for AF, 45 for breast cancer, and 55 for prostate cancer).
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Table S6. Hazard ratios (HR) and 95% confidence intervals (CI) per standard deviation increment in FINRISK, obtained 
from Cox proportional hazards models. 
 
  N total N cases HR (95% CI) p 
Incident coronary heart disease 20,188 2,197 1.25 (1.18-1.32) 1.74x10-14 
Incident type 2 diabetes 21,030 1,346 1.70 (1.63-1.78) 8.82x10-133 
Incident atrial fibrillation or flutter 19,691 1,431 1.62 (1.54-1.70) 8.85x10-78 
Incident breast cancer 11,332 404 1.75 (1.59-1.92) 2.61x10-30 
Incident prostate cancer 10,258 444 1.88 (1.71-2.06) 4.74x10-41 
 
All tests were two-tailed. 
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Table S7. Hazard ratios (HR) and 95% confidence intervals (CI) for polygenic risk score (PRS) bins in FINRISK, 
obtained from Cox proportional hazards models.  
 
 
  HR (95% CI) p N cases / N contols 
CHD PRS    
<2.5 0.65 (0.47-0.89) 0.008 39 / 466 
2.5-20 0.81 (0.72-0.92) 0.001 313 / 3,220 
20-80 1 (reference) - 1,274 / 10,838 
80-97.5 1.35 (1.22-1.50) 2.45x10-8 471 / 3,062 
>97.5 2.42 (1.97-2.97) 2.21x10-17 100 / 405 
T2D PRS    
<2.5 0.23 (0.14-0.38) 7.14x10-9 16 / 513 
2.5-20 0.50 (0.43-0.58) 2.80x10-21 224 / 3,476 
20-80 1 (reference) - 1,406 / 11,278 
80-97.5 1.90 (1.73-2.08) 4.44x10-43 719 / 2,981 
>97.5 2.99 (2.52-3.54) 1.44x10-36 151 / 378 
AF PRS    
<2.5 0.44 (0.26-0.73) 0.002 15 / 478 
2.5-20 0.60 (0.50-0.72) 1.69x10-8 143 / 3,303 
20-80 1 (reference) - 779 / 11,035 
80-97.5 1.94 (1.72-2.19) 4.28x10-27 406 / 3,039 
>97.5 3.19 (2.56-3.98) 8.67x10-25 88 / 405 
Breast cancer PRS    
<2.5 0.43 (0.16-1.16) 0.09 4 / 280 
2.5-20 0.44 (0.30-0.65) 3.58x10-5 29 / 1,954 
20-80 1 (reference) - 221 / 6,577 
80-97.5 1.94 (1.56-2.42) 3.90x10-9 123 / 1,860 
>97.5 3.05 (2.04-4.55) 5.34x10-8 27 / 257 
Prostate cancer PRS    
<2.5 0.10 (0.01-0.73) 0.02 1 / 256 
2.5-20 0.38 (0.25-0.58) 4.90x10-6 25 / 1,770 
20-80 1 (reference) - 233 / 5,921 
80-97.5 2.14 (1.74-2.64) 6.58x10-13 146 / 1,649 
>97.5 3.93 (2.79-5.53) 3.90x10-15 39 / 218 
    
CHD = coronary heart disease, AF = atrial fibrillation or flutter, T2D = type 2 diabetes, PRS = polygenic risk 
score. Only incident cases included. All tests were two-tailed. 
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Table S8. The prospective epidemiological and disease-based cohorts, and hospital biobank samples in FinnGen Data 
Freeze 3. 
 
 
Cohort N 
Auria biobank* 9,967 
Blood Service biobank 13,222 
Borealis biobank* 1,368 
Botnia Family 1,216 
Botnia New 6 
Botnia PPP 4,856 
Botnia Sib-Helsinki 431 
Corogene 4,495 
Eastern Finland biobank* 1,965 
FinHealth 2017 5,783 
FINRISK 1992-2012 29,550 
GeneRISK 6,960 
Health 2000 6,602 
Health 2011 711 
Helsinki biobank* 21,014 
Kuusamo 2011 145 
Migraine 7,732 
SUPER 4,402 
Tampere biobank* 1,973 
THL Diabetes 6,983 
Twins 5,919 
Sum 135,300 
 
 
*Hospital-based biobanks 
 
 9 
Table S9. Disease endpoint definitions. 
 
 Additional definitions 
Only main 
diagnosis 
accepted 
ICD-10 ICD-9 ICD-8 ICD-10 exclusions 
Cause of 
death 
ICD-10 
Cause of 
death 
ICD-9 
Cause of 
death 
ICD-8 
Cause of 
death 
ICD-10 
exclu-
sions 
Cause of 
death 
ICD-9 
exclu-
sions 
Topo-
graphical 
codes* 
Coronary heart 
disease 
Myocardial infarction|Myocardial 
infarction, strict|Complications 
following myocardial infarction|Prior 
myocardial infactrion|Angina 
pectoris|Other coronary 
atherosclerosis|Coronary artery bypass 
graft**|Coronary angioplasty** 
           
Major coronary 
heart disease event 
Myocardial infarction|Coronary artery 
bypass graft|Coronary angioplasty Yes 
I20.0 | I21 | 
I22 
410 | 
4110 
410 | 
411.0 
 I2[1-5] | I46 | R96 
| R98 
41[0-4] | 
798 
41[0-4] | 
798 
 7980A  
Myocardial 
infarction, strict 
 Yes I21 | I22 410 410  I21 | I22 410 410    
Myocardial 
infarction 
  I21 | I22 410 410  I21 | I22 410 410    
Complications 
following myocardial 
infarction 
  I23 - -  I23 - -    
Old myocardial 
infarction  
  I25.2 412 412  I25.3 412 412    
Angina pectoris   I20 413 | 411[0-1] 413 
 I20 413 | 411[0-1] 413 
   
Other coronary 
atheroclerosis 
  I25 | I24 | 
Z95.1 | T82.2 
414 | 
9960A 414 I25.3 
I25 | I24 | 
Z95.1 | 
T82.2 
414 | 
9960A 414 I25.3 
  
             
             
Atrial fibrillation and 
flutter 
Eligibility for special reimbursement for 
apixaban, dabigatran, edoxaban, 
rivaroxaban or dronedarone for ICD-10 
I48 
 I48 4273 427.92  I48 4273 427.92    
 10 
Malignant neoplasm 
of breast / breast 
cancer 
Reimbursement for medications used for 
treating breast cancer 
          C50 
Malignant neoplasm 
of prostate / prostate 
cancer 
Reimbursement for medications used for 
treating prostate cancer 
          C61 
Type 2 diabetes*** 
Any type 2 diabetes diagnosis defined 
below | Medication purchases for ATC 
A10B, Blood glucose lowering drugs, 
excluding insulins. 
    E10[0-9]       
Type 2 diabetes with 
coma 
  E11.0 2502A -  E11.0 2502A     
Type 2 diabetes with 
ketoacidosis 
  E11.1 2501A -  E11.1 2501A     
Type 2 diabetes with 
renal complications 
  E11.2 2503A -  E11.2 2503A     
Type 2 diabetes with 
ophthalmic 
complications 
  E11.3 2504A -  E11.3 2504A     
Type 2 diabetes with 
neurological 
complications 
  E11.4 2505A -  E11.4 2505A     
Type 2 diabetes with 
peripheral circulatory 
complications 
  E11.5 2506A -  E11.5 2506A     
Type 2 diabetes with 
other specified/ 
multiple/unspecified 
complications 
Eligibility for medication 
reimbursement with ICD-10 E11 
 E11[6-8] 2507A | 2508A - 
 E11[6-8] 2507A | 2508A 
    
Type 2 diabetes 
without complications 
  E11.9 2500A -  E11.9 2500A     
* The International Classification of Diseases for Oncology, Third Edition (ICD-O-3). **Procedure code identified at hospital discharge or from 
the nationwide register of invasive cardiac procedures. *** In FinnGen analyses, individuals with type 1 diabetes were excluded from cases (ICD-10 E10[0-9], ICD-9 250[0-8]B as a hospital discharge diagnosis or cause of 
death, or E10 for medication reimbursement) 
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Table S10. Genome-wide association studies used for constructing the polygenic risk scores and the number of variants in the final scores. 
 
 
 
 
GWAS 
summary 
statistics 
source 
Article link Data download link 
Most recent 
access to data 
download  
SNPs in 
discovery GWAS 
SNPs in PRS 
calculation LD radius 
Additional 
information 
Coronary heart 
disease 
UKBB 
SAIGE 
https://www.nature.com/a
rticles/s41588-018-0184-y 
https://www.dropbox.com/sh/wuj4y
8wsqjz78om/AAACfAJK54KtvnzS
TAoaZTLma?dl=0  
Nov 2, 2018 28 345 446 6 412 950 4 000 
PheCode 411 
Ischemic heart 
disease 
Type 2 diabetes Mahajan et al 2018 
https://www.nature.com/a
rticles/s41588-018-0241-6 
http://www.diagram-
consortium.org/downloads.html Dec 21, 2018 23 465 133 6 437 380 4 000 
 Not adjusted for 
BMI   
Atrial fibrillation 
and flutter 
Nielsen et al 
2018 
https://www.nature.com/a
rticles/s41588-018-0171-3 
http://csg.sph.umich.edu/willer/publ
ic/afib2018/ Dec 21, 2018 34 740 187 6 171 733 4 000 
 
Breast cancer Michailidou et al 2017 
https://www.nature.com/a
rticles/nature24284 
http://bcac.ccge.medschl.cam.ac.uk/
bcacdata/oncoarray/gwas-icogs-
and-oncoarray-summary-results/ 
Dec 21, 2018 11 792 358 6 390 808 4 000  
Breast cancer, 
estrogen receptor-
positive 
Michailidou 
et al 2017 
https://www.nature.com/a
rticles/nature24284 
http://bcac.ccge.medschl.cam.ac.uk/
bcacdata/oncoarray/gwas-icogs-
and-oncoarray-summary-results/ 
Dec 21, 2018 11 784 434 6 390 799 4 000  
Breast cancer, 
estrogen receptor-
negative 
Michailidou 
et al 2017 
https://www.nature.com/a
rticles/nature24284 
http://bcac.ccge.medschl.cam.ac.uk/
bcacdata/oncoarray/gwas-icogs-
and-oncoarray-summary-results/ 
Dec 21, 2018 11 784 725 6 390 805 4 000  
Prostate cancer Schumacher et al 2018 
https://www.nature.com/a
rticles/s41588-018-0142-8 
http://practical.icr.ac.uk/blog/?page
_id=8088 Dec 21, 2018 20 734 509 6 606 785 4 000 
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Table S11. The LDpred algorithm uses a tuning parameter p for denoting the fraction of variants assumed to be causal 
for the disease. The PRS with the highest C-index (bolded) in FINRISK (total n = 21,813),  was chosen for the subsequent 
analyses. 
 
 
Fraction of causal 
markers 
C-index 
Coronary heart disease 0.0001* 0.8163 
 0.0003* 0.8162 
 0.001* 0.8163 
 0.003 0.8203 
 0.01 0.8195 
 0.03 0.8188 
 0.1 0.8184 
 0.3 0.8183 
 1 0.8183 
 inf 0.8183 
Type 2 diabetes 0.0001* 0.7022 
 0.0003* 0.7043 
 0.001* 0.7033 
 0.003* 0.7033 
 0.01* 0.7089 
 0.03* 0.7091 
 0.1 0.7374 
 0.3 0.7417 
 1 0.7402 
 inf 0.7398 
Atrial fibrillation or flutter 0.0001* 0.7912 
 0.0003* 0.7915 
 0.001* 0.7921 
 0.003* 0.7916 
 0.01* 0.7942 
 0.03 0.8135 
 0.1 0.8107 
 0.3 0.8082 
 1 0.8057 
 inf 0.8055 
Prostate cancer 0.0001* 0.8076 
 0.0003* 0.8077 
 0.001* 0.8096 
 0.003 0.8140 
 0.01 0.8416 
 0.03 0.8341 
 0.1 0.8270 
 0.3 0.8237 
 1 0.8224 
 inf 0.8223 
Breast cancer 0.0001* 0.6426 
 0.0003* 0.6403 
 0.001* 0.6454 
 0.003* 0.6490 
 0.01* 0.6422 
 13 
 0.03 0.7042 
 0.1 0.6955 
 0.3 0.6892 
 1 0.6852 
 inf 0.6853 
Breast cancer, estrogen receptor-positive 0.0001* 0.6404 
 0.0003* 0.6421 
 0.001* 0.6434 
 0.003* 0.6450 
 0.01* 0.6479 
 0.03 0.6990 
 0.1 0.6912 
 0.3 0.6868 
 1 0.6834 
 inf 0.6833 
Breast cancer, estrogen receptor-negative 0.0001* 0.6403 
 0.0003* 0.6410 
 0.001* 0.6405 
 0.003 0.6511 
 0.01 0.6472 
 0.03 0.6449 
 0.1 0.6438 
 0.3 0.6435 
 1 0.6434 
 inf 0.6432 
 
*One or multiple chromosomes failed to converge. C-index from Cox proportional hazards model (follow-up as time scale), stratified by sex and 
adjusting for age, ten first principal components of ancestry, FINRISK survey collection year, and genotyping array. Only incident cases included. 
 
